Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H17Cl3O3 |
| Molecular Weight | 423.717 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(OCC2=CC=C(COC3=C(Cl)C=CC=C3Cl)C=C2)C(Cl)=C1
InChI
InChIKey=XXMDDBVNWRWNCW-UHFFFAOYSA-N
InChI=1S/C21H17Cl3O3/c1-25-16-9-10-20(19(24)11-16)26-12-14-5-7-15(8-6-14)13-27-21-17(22)3-2-4-18(21)23/h2-11H,12-13H2,1H3
| Molecular Formula | C21H17Cl3O3 |
| Molecular Weight | 423.717 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pocapavir is a capsid-binding molecule. It is a capsid inhibitor that blocks virus uncoating and viral RNA release into cells, which in turn prevents virus replication. Pocapavir is a potent, selective, anti-enterovirus molecule with in vitro and in vivo activities. Antiviral testing against viruses of the 15 most commonly isolated enterovirus serotypes indicates that pocapavir inhibits 80% of the immunotypes (154 viruses) at a concentration that is within the levels of the molecule achievable in plasma after oral dosing in higher animals. Persistent low viral load after therapy completion may indicate lack of antiviral effect from pocapavir for neonatal enteroviral sepsis treatment. Pocapavir had been in phase II clinical trial for the treatment of poliomyelitis but no recent reports on development were identified.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir. | 2018-05-18 |
|
| Neonatal nonpolio enterovirus and parechovirus infections. | 2018-04 |
|
| Neonatal Enterovirus Myocarditis With Severe Dystrophic Calcification: Novel Treatment With Pocapavir. | 2017-06-12 |
|
| Completing Polio Eradication: The Case for Antiviral Drugs. | 2017-02-01 |
|
| Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model. | 2017-02-01 |
|
| Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy. | 2015-10-07 |
|
| First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis. | 2015-01 |
|
| Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. | 2014-11-01 |
|
| H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. | 2014-10 |
|
| Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. | 2014-08 |
|
| The enteroviruses: problems in need of treatments. | 2014-01 |
|
| Highlights in antiviral drug research: antivirals at the horizon. | 2013-11 |
|
| Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. | 2013-05 |
|
| Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. | 2012-11 |
|
| Combating enterovirus replication: state-of-the-art on antiviral research. | 2012-01-15 |
|
| Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice. | 2011-08 |
|
| Towards the design of combination therapy for the treatment of enterovirus infections. | 2011-06 |
|
| Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. | 2011 |
|
| In vitro antiviral activity of V-073 against polioviruses. | 2009-10 |
|
| Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. | 1997-07-15 |
|
| SCH 48973: a potent, broad-spectrum, antienterovirus compound. | 1997-06 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:56:53 GMT 2025
by
admin
on
Mon Mar 31 20:56:53 GMT 2025
|
| Record UNII |
4ILA3VOV97
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/12/1021
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
357811
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9602
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
C132145
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
100000181867
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
1455
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
4ILA3VOV97
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
146949-21-5
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
DTXSID00163548
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
